China NMPA Inspection - Guangzhou Daifen Cosmetics Co., Ltd. - March 21, 2018

Guangzhou Daifen Cosmetics Co., Ltd. was subjected to an unannounced supervision inspection by the National Food and Drug Administration and Guangdong Provincial Food and Drug Administration, with findings published on March 21, 2018. The inspection, conducted under the "Key Points for Cosmetics Production License Inspection," revealed 8 serious and 15 general defects, indicating severe non-compliance with "Cosmetics Production Licensing Work Standards." Significant violations included critical management positions being held part-time, leading to inadequate oversight, neglected staff training and health checks, and a pervasive lack of complete records for production, inspections, training, and sales. The company failed to inspect raw materials, packaging, and intermediate products, and could not provide original inspection records for several finished products. Facility and equipment issues included unsanitary production areas, absence of environmental controls in warehouses, and uncalibrated testing instruments. Material management was deficient, with missing inventory records and the unauthorized storage of an unregistered product, "Nobige High-Efficiency Scar Repair Ointment," lacking proper documentation or ingredient sourcing. The production process also lacked clear batch definitions, hindering product traceability. Consequently, Guangzhou Daifen Cosmetics Co., Ltd. was ordered to suspend all production and sales. Operations can only resume after thorough rectification, confirmed compliance by the Guangdong Provincial Food and Drug Administration, and subsequent reporting to the State Administration for Market Regulation.